Anti-IL-23 biologic hit positive results in a 19-dog IBD pilot trialNew veterinary graduates have clinical foundations but lack the volume fluency practices expectBoard-certified internist says DVMs need to shape AI tools before consumer tech companies doBrakke Consulting framed fuel costs as a pass-through in its October newsletterAVMA greenlights Maryland Eastern Shore vet school, first public HBCU programAntech Accuplex showed higher Ehrlichia sensitivity than IDEXX SNAP 4Dx Plus in a JAVMA studyPractices underuse credentialed veterinary technicians while posting open positionsVetsource data shows practices unlikely to see pandemic puppy boom in senior yearsAnti-IL-23 biologic hit positive results in a 19-dog IBD pilot trialNew veterinary graduates have clinical foundations but lack the volume fluency practices expectBoard-certified internist says DVMs need to shape AI tools before consumer tech companies doBrakke Consulting framed fuel costs as a pass-through in its October newsletterAVMA greenlights Maryland Eastern Shore vet school, first public HBCU programAntech Accuplex showed higher Ehrlichia sensitivity than IDEXX SNAP 4Dx Plus in a JAVMA studyPractices underuse credentialed veterinary technicians while posting open positionsVetsource data shows practices unlikely to see pandemic puppy boom in senior years
The WireBy The VeterinaryPracticeNow Desk2 min readOctober 26, 2026
Anti-IL-23 biologic hit positive results in a 19-dog IBD pilot trial
VETmAb Biosciences announced positive clinical proof-of-concept results for VMB-C001a in a 105-day placebo-controlled pilot study of 19 client-owned dogs.
VETmAb Biosciences reported positive proof-of-concept results for VMB-C001a, a long-acting monoclonal antibody that targets IL-23 in dogs with chronic inflammatory enteropathy, commonly called inflammatory bowel disease, according to Today's Veterinary Business.
Whether this gives you a steroid-sparing option now
The company ran a 105-day placebo-controlled pilot study in 19 client-owned dogs and reported positive results. This is proof-of-concept work. The FDA Center for Veterinary Medicine granted the drug eligibility for the expanded conditional approval pathway, which can accelerate commercialization while full effectiveness studies are completed.
The pilot showed positive clinical findings. The study enrolled client-owned dogs, not research colony animals, which signals potential for real-world adoption if later-stage data hold.
The pathway this targets and why it matters for the IBD cases you manage today
VMB-C001a targets IL-23, a cytokine involved in chronic inflammation. Current canine IBD protocols rely on steroids and immunosuppressants (prednisone tapers, azathioprine, cyclosporine) which carry long-term side effect risks that drive owner pushback and complicate case management. According to Today's Veterinary Business, there are currently no FDA-approved therapies for canine chronic inflammatory enteropathy.
Denise Bevers, CEO of VETmAb, said in a statement that the company's approach of taking human drug targets and adapting them for veterinary use has been validated by the trial data, and the results "are clinical proof that our model works."
What early-stage proof-of-concept data cannot tell you
This is a 19-dog pilot. The company reported positive results. The source did not provide detailed efficacy data, response rates, safety profiles, or how treatment success was measured.
Biologic pricing will determine whether this becomes a referral-only tool or a primary-care option. If the drug reaches market at a price point accessible to typical IBD cases, it changes the formulary conversation for owner-veterinarians planning three to five years out. If it prices as a specialty product, it becomes a referral decision for the associate managing the case that isn't responding to prednisone.
This is a canine IBD biologic with placebo-controlled proof-of-concept data, and it's early enough that tracking development now lets you plan client education and formulary decisions if it reaches market. The company reported positive proof-of-concept results in a 19-dog pilot. We'd watch for further study announcements and any disclosure of detailed efficacy measures and safety data.
For the associate two years out managing IBD cases with prednisone tapers and azathioprine, this doesn't change your protocol today. For the owner-veterinarian deciding whether to add a specialist or expand internal medicine capacity, this is one data point in a longer trend: biologics developed for human inflammatory disease are being adapted for veterinary use, and if pricing and efficacy data hold, they will reshape chronic disease management in primary care.
Get the next issue in your inbox. Free, weekly, no fluff.
